Individualized Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administration in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Nurse's Role.

Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% offers potential improvements in patient independence and tolerability versus intravenous immunoglobulin (IVIG) when used for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). fSCIG 10% also requires less frequent infusions and fewer infusion sites than conventional subcutaneous immunoglobulin (subcutaneous immunoglobulin without hyaluronidase). The ADVANCE-CIDP 1 study demonstrated fSCIG 10% efficacy and safety in preventing CIDP relapse and positive responses from patients in terms of satisfaction and treatment preference. Extensive guidance was provided to nurses during the conduct of ADVANCE-CIDP 1, including delivery of a "Train the Trainer" program by clinical trial educators to support study-site nurses. Consequently, ADVANCE-CIDP 1 has generated a valuable source of practical guidance for nurses. This review describes the key role of nursing professionals in facilitating successful transition from IVIG to subcutaneous therapy in patients with CIDP and draws on experience from ADVANCE-CIDP 1 to help equip nursing staff with the knowledge and confidence to support patients with CIDP initiating fSCIG 10% as a maintenance treatment.